Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2

SARS-CoV-2 Omicron BA.2.75 has diversified into multiple subvariants with additional spike mutations, and several are expanding in prevalence, particularly CH.1.1 and BN.1. Here, we investigated the viral receptor affinities and neutralization evasion properties of major BA.2.75 subvariants actively circulating in different regions worldwide. We found two distinct evolutionary pathways and three newly identified mutations that shaped the virological features of these subvariants. One phenotypic group exhibited a discernible decrease in viral receptor affinities, but a noteworthy increase in resistance to antibody neutralization, as exemplified by CH.1.1, which is apparently as resistant as XBB.1.5. In contrast, a second group demonstrated a substantial increase in viral receptor affinity but only a moderate increase in antibody evasion, as exemplified by BN.1. We also observed that all prevalent SARS-CoV-2 variants in the circulation presently, except for BN.1, exhibit profound levels of antibody evasion, suggesting this is the dominant determinant of virus transmissibility today.

[1]  F. Alt,et al.  An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion , 2022, Science Immunology.

[2]  G. Pantaleo,et al.  Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys , 2022, Nature Microbiology.

[3]  R. Bloomquist,et al.  PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2 , 2022, mSphere.

[4]  D. Stuart,et al.  Potent cross-reactive antibodies following Omicron breakthrough in vaccinees , 2022, Cell.

[5]  J. Chan,et al.  An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses , 2022, Science Translational Medicine.

[6]  C. Rice,et al.  Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins , 2022, Immunity.

[7]  Chaim A. Schramm,et al.  Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants , 2021, Science.

[8]  D. Stuart,et al.  Antibody evasion by the P.1 strain of SARS-CoV-2 , 2021, Cell.

[9]  M. Beltramello,et al.  Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms , 2020, Science.

[10]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[11]  M. Beltramello,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[12]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[13]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.